Publications searcher

The science produced by our scientists is very important. In 2024, 1,501 papers were published in scientific journals with an average impact factor of over 7.13 points.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

PMID: 30156984
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2018
Reference: J Clin Oncol. 2018 Nov 1;36(31):3101-3109. doi: 10.1200/JCO.2018.77.7326. Epub 2018 Aug 29.
Impact factor:
Publication type: Paper in international publication
Authors: Ahn, Myung-Ju; Akimov, Mikhail; Chia, Vincent; Felip, Enriqueta; Glaser, Sabine; Kim, Dong-Wan; Lee, Dae Ho; Liu, Xiaoqing; Peng, Bin; Pultar, Philippe et al.
DOI: 10.1200/JCO.2018.77.7326

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors.

PMID: 29242283
Journal: ONCOLOGIST
Year: 2018
Reference: Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.
Impact factor: 5.306
Publication type: Paper in international publication
Authors: Lombard-Bohas, Catherine, Salazar, Ramon, Garcia-Carbonero, Rocio, Libutti, Steven K, Hendifar, Andrew E, Custodio, Ana, Guimbaud, Rosine, Capdevila, Jaume, Reed, Nicholas, Walenkamp, Annemiek et al.
DOI: 10.1634/theoncologist.2017-0144

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors.

PMID: 29242283
Journal: ONCOLOGIST
Year: 2018
Reference: Oncologist. 2018 Jul;23(7):766-e90. doi: 10.1634/theoncologist.2017-0144. Epub 2017 Dec 14.
Impact factor:
Publication type: Paper in international publication
Authors: Capdevila, Jaume; Custodio, Ana; Garcia-Carbonero, Rocio; Grande, Enrique; Guimbaud, Rosine; Hendifar, Andrew E; Klumpen, Heinz-Josef; Kong, Oliver; Libutti, Steven K; Lombard-Bohas, Catherine et al.
DOI: 10.1634/theoncologist.2017-0144

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

PMID: 29182496
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2018
Reference: J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
Impact factor: 26.303
Publication type: Paper in international publication
Authors: Javle, Milind, Lowery, Maeve, Shroff, Rachna T, Weiss, Karl Heinz, Springfeld, Christoph, Bekaii-Saab, Tanios, Abou-Alfa, Ghassan K, Borad, Mitesh J, Ramanathan, Ramesh K, Goyal, Lipika et al.
DOI: 10.1200/JCO.2017.75.5009

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

PMID: 29182496
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2018
Reference: J Clin Oncol. 2018 Jan 20;36(3):276-282. doi: 10.1200/JCO.2017.75.5009. Epub 2017 Nov 28.
Impact factor:
Publication type: Paper in international publication
Authors: Abou-Alfa, Ghassan K; Bekaii-Saab, Tanios; Borad, Mitesh J; Borbath, Ivan; Chen, Li-Tzong; Choo, Su Pin; Ciombor, Kristen; El-Khoueiry, Anthony; Finn, Richard S; Goyal, Lipika et al.
DOI: 10.1200/JCO.2017.75.5009

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

PMID: 29198055
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2018
Reference: Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2.
Impact factor: 3.605
Publication type: Paper in international publication
Authors: Han, H S, Pistilli, B, Pluard, T, Urruticoechea, A, Farci, D, Kong, A, Bachelot, T, Chan, S, Robinson, D, Mouhaer, S L et al.
DOI: 10.1007/s10549-017-4596-7

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

PMID: 29198055
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2018
Reference: Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2.
Impact factor:
Publication type: Paper in international publication
Authors: Bachelot, T; Chan, S; Farci, D; Han, H S; Jerusalem, G; Kong, A; Massacesi, C; Mouhaer, S L; Pistilli, B; Pluard, T et al.
DOI: 10.1007/s10549-017-4596-7

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

PMID: 29177953
Journal: Targeted Oncology
Year: 2018
Reference: Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9.
Impact factor: 3.877
Publication type: Paper in international publication
Authors: Lopez-Martin, Jose Antonio, Martin-Liberal, Juan, Lopez-Pousa, Antonio, Martinez-Trufero, Javier, Martin-Broto, Javier, Cubedo, Ricardo, Lavernia, Javier, Redondo, Andres, Tirado, Oscar M, Garcia-Del-Muro, Xavier et al.
DOI: 10.1007/s11523-017-0539-9

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

PMID: 29177953
Journal: Targeted Oncology
Year: 2018
Reference: Target Oncol. 2018 Feb;13(1):81-87. doi: 10.1007/s11523-017-0539-9.
Impact factor:
Publication type: Paper in international publication
Authors: Cubedo, Ricardo; Garcia-Del-Muro, Xavier; Lavernia, Javier; Lopez-Martin, Jose Antonio; Lopez-Pousa, Antonio; Martin-Broto, Javier; Martin-Liberal, Juan; Martinez-Trufero, Javier; Mulet-Margalef, Nuria; Redondo, Andres et al.
DOI: 10.1007/s11523-017-0539-9

Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

PMID: 29793946
Journal: CLINICAL CANCER RESEARCH
Year: 2018
Reference: Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.
Impact factor: 10.199
Publication type: Paper in international publication
Authors: Dickler, Maura N, Saura, Cristina, Richards, Donald, Krop, Ian, Cervantes, Andres, Bedard, Phillipe L, Patel, Manish R, Pusztai, Lajos, Oliveira, Mafalda, Cardenas, Alison K et al.
DOI: 10.1158/1078-0432.CCR-18-0613

Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

PMID: 29793946
Journal: CLINICAL CANCER RESEARCH
Year: 2018
Reference: Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.
Impact factor:
Publication type: Paper in international publication
Authors: Baselga, Jose; Bedard, Phillipe L; Cardenas, Alison K; Cervantes, Andres; Cui, Na; Dickler, Maura N; Hsu, Jerry Y; Krop, Ian; Oliveira, Mafalda; Patel, Manish R et al.
DOI: 10.1158/1078-0432.CCR-18-0613

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.

PMID: 29506988
Journal: CLINICAL CANCER RESEARCH
Year: 2018
Reference: Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.
Impact factor: 10.199
Publication type: Paper in international publication
Authors: Penuel, Elicia, Hill, Andrew Graham, Findlay, Michael, Burge, Matthew, Jackson, Christopher, Garcia Alfonso, Pilar, Samuel, Leslie, Ganju, Vinod, Karthaus, Meinolf, Amatu, Alessio et al.
DOI: 10.1158/1078-0432.CCR-17-0646

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.

PMID: 29506988
Journal: CLINICAL CANCER RESEARCH
Year: 2018
Reference: Clin Cancer Res. 2018 May 15;24(10):2276-2284. doi: 10.1158/1078-0432.CCR-17-0646. Epub 2018 Mar 5.
Impact factor:
Publication type: Paper in international publication
Authors: Amatu, Alessio; Bridgewater, John; Burge, Matthew; Coveler, Andrew L; Di Bartolomeo, Maria; Findlay, Michael; Ganju, Vinod; Garcia Alfonso, Pilar; Hanley, William; Hidalgo, Manuel et al.
DOI: 10.1158/1078-0432.CCR-17-0646

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

PMID: 29756206
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2018
Reference: Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9.
Impact factor: 7.36
Publication type: Paper in international publication
Authors: Verslype, Chris, Raymond, Eric, Cubillo, Antonio, Schueler, Armin, Zhao, Charles, Hammel, Pascal, Radenkovic, Dejan, Manojlovic, Nebojsa, Bazin, Igor, Van Cutsem, Eric et al.
DOI: 10.1002/ijc.31603

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

PMID: 29756206
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2018
Reference: Int J Cancer. 2018 Oct 15;143(8):2053-2064. doi: 10.1002/ijc.31603. Epub 2018 Aug 9.
Impact factor:
Publication type: Paper in international publication
Authors: Bazin, Igor; Canon, Jean-Luc; Cubillo, Antonio; Hammel, Pascal; Hidalgo, Manuel; Macarulla, Teresa; Manojlovic, Nebojsa; Poddubskaya, Elena; Radenkovic, Dejan; Raymond, Eric et al.
DOI: 10.1002/ijc.31603

PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.

PMID: 29339541
Journal: CANCER RESEARCH
Year: 2018
Reference: Cancer Res. 2018 Apr 1;78(7):1805-1819. doi: 10.1158/0008-5472.CAN-17-1346. Epub 2018 Jan 16.
Impact factor: 9.13
Publication type: Paper in international publication
Authors: Dopeso, Higinio, Jiao, Hui-Ke, Cuesta, Angel M, Henze, Anne-Theres, Jurida, Liane, Kracht, Michael, Acker-Palmer, Amparo, Acker, Till, Garvalov, Boyan K et al.
DOI: 10.1158/0008-5472.CAN-17-1346

PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.

PMID: 29339541
Journal: CANCER RESEARCH
Year: 2018
Reference: Cancer Res. 2018 Apr 1;78(7):1805-1819. doi: 10.1158/0008-5472.CAN-17-1346. Epub 2018 Jan 16.
Impact factor:
Publication type: Paper in international publication
Authors: Acker, Till; Acker-Palmer, Amparo; Cuesta, Angel M; Dopeso, Higinio; Garvalov, Boyan K; Henze, Anne-Theres; Jiao, Hui-Ke; Jurida, Liane; Kracht, Michael et al.
DOI: 10.1158/0008-5472.CAN-17-1346

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

PMID: 29691292
Journal: CLINICAL CANCER RESEARCH
Year: 2018
Reference: Clin Cancer Res. 2018 Aug 1;24(15):3767-3780. doi: 10.1158/1078-0432.CCR-18-0177. Epub 2018 Apr 24.
Impact factor: 10.199
Publication type: Paper in international publication
Authors: Veiga, Sonia Rosa, Ge, Xuemei, Mercer, Carol A, Hernandez-Alvarez, Maria Isabel, Thomas, Hala Elnakat, Hernandez-Losa, Javier, Ramon Y Cajal, Santiago, Zorzano, Antonio, Thomas, George, Kozma, Sara C et al.
DOI: 10.1158/1078-0432.CCR-18-0177

Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR.

PMID: 32177313
Journal: ANNALS OF ONCOLOGY
Year: 2018
Reference: Ann Oncol. 2018 Jun;29 Suppl 5:v91. doi: 10.1093/annonc/mdy151.323. Epub 2020 Jan 7.
Impact factor: 13.926
Publication type: Letter or abstract
Authors: Veiga, S, Ge, X, Mercer, C, Hernandez-Alvarez, M, Thomas, H, Hernandez-Losa, J, Cajal, S R Y, Zorzano, A, Thomas, G, Kozma, S et al.
DOI: 10.1093/annonc/mdy151.323

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

PMID: 29691292
Journal: CLINICAL CANCER RESEARCH
Year: 2018
Reference: Clin Cancer Res. 2018 Aug 1;24(15):3767-3780. doi: 10.1158/1078-0432.CCR-18-0177. Epub 2018 Apr 24.
Impact factor:
Publication type: Paper in international publication
Authors: Ge, Xuemei; Hernandez-Alvarez, Maria Isabel; Hernandez-Losa, Javier; Kozma, Sara C; Mercer, Carol A; Ramon Y Cajal, Santiago; Thomas, George; Thomas, Hala Elnakat; Veiga, Sonia Rosa; Zorzano, Antonio et al.
DOI: 10.1158/1078-0432.CCR-18-0177

Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR.

PMID: 32177313
Journal: ANNALS OF ONCOLOGY
Year: 2018
Reference: Ann Oncol. 2018 Jun;29 Suppl 5:v91. doi: 10.1093/annonc/mdy151.323. Epub 2020 Jan 7.
Impact factor:
Publication type: Letter or abstract
Authors: Cajal, S R Y; Ge, X; Hernandez-Alvarez, M; Hernandez-Losa, J; Kozma, S; Mercer, C; Thomas, G; Thomas, H; Veiga, S; Zorzano, A et al.
DOI: 10.1093/annonc/mdy151.323

Phenotype-modifying Factors in Hypertrophic Cardiomyopathy.

PMID: 29844006
Journal: REVISTA ESPANOLA DE CARDIOLOGIA
Year: 2018
Reference: Rev Esp Cardiol (Engl Ed). 2018 Sep;71(9):770. doi: 10.1016/j.rec.2018.03.021. Epub 2018 May 26.
Impact factor: 5.166
Publication type: Letter or abstract
Authors: Limeres Freire, Javier et al.
DOI: 10.1016/j.rec.2018.03.021

Phenotype-modifying Factors in Hypertrophic Cardiomyopathy.

PMID: 29844006
Journal: REVISTA ESPANOLA DE CARDIOLOGIA
Year: 2018
Reference: Rev Esp Cardiol (Engl Ed). 2018 Sep;71(9):770. doi: 10.1016/j.rec.2018.03.021. Epub 2018 May 26.
Impact factor:
Publication type: Letter or abstract
Authors: Limeres Freire, Javier et al.
DOI: 10.1016/j.rec.2018.03.021

Phenotypes, endotypes and biomarkers in anaphylaxis: current insights.

PMID: 30048251
Journal: Current Opinion in Allergy and Clinical Immunology
Year: 2018
Reference: Curr Opin Allergy Clin Immunol. 2018 Oct;18(5):370-376. doi: 10.1097/ACI.0000000000000472.
Impact factor: 3.544
Publication type: Review in international publication
Authors: Sala-Cunill, Anna, Guilarte, Mar, Cardona, Victoria et al.
DOI: 10.1097/ACI.0000000000000472

Publications

Publications searcher

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Endothelial Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors.

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naive Advanced Pancreatic Neuroendocrine Tumors.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.

Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Phase II Study of Taselisib (GDC0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.

Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.

PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.

PHD3 controls lung cancer metastasis and resistance to EGFR inhibitors through TGFalpha.

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR.

Phenformin-Induced Mitochondrial Dysfunction Sensitizes Hepatocellular Carcinoma for Dual Inhibition of mTOR.

Phenformin-induced mitochondrial dysfunction sensitizes hepatocellular carcinoma for dual inhibition of mTOR.

Phenotype-modifying Factors in Hypertrophic Cardiomyopathy.

Phenotype-modifying Factors in Hypertrophic Cardiomyopathy.

Phenotypes, endotypes and biomarkers in anaphylaxis: current insights.

Patronage:

Collaborating:

Accreditations: